C Diff Treatment

Not all probiotics are created equal. In a new study, researchers found that certain enzymes within a class known as bile salt hydrolases (BSHs) can restrict Clostridioides difficile (C. diff.) colonization by both altering existing bile acids and by creating a new class of bile acids within the gut's microbial environment. The work could lead to "designer" probiotics that protect against disease by introducing specific BSHs to the gut after antibiotic treatment.

A team of investigators from Mass General Brigham's founding members, Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH), has identified metabolic strategies used by Clostridioides ...

Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital identified new targets for small molecule drugs to counter Clostridioides difficile colonization and infection (CDI) in the gut and provide a new approach to rapidly define microbial metabolism for other applications.

SUMMARY: Clostridioides difficile is a gram-positive spore-forming and toxin-producing bacteria that can cause disease ranging from mild diarrhea to severe and even fatal colonic inflammation. It is spread via the fecal-oral route. This infection often occurs after antibiotic use, as antibiotics change the normal gut flora and allows this bacterium to grow and produce its […]

A young woman who dealt with reoccurring Clostridioides difficile (CDI) in a short amount of time recounts her experience and how getting into a clinical trial made the difference in resolving her condition and getting her back to good health and her family.

Although the recurrence rate with FEPD was numerically lower than that observed with FCD, we have not been able to show that the recurrence rate of CDI is different depending on the dosage regimen of fidaxomicin. Clinical trials or large observational studies comparing the two dosing regimens of fid …

Although the recurrence rate with FEPD was numerically lower than that observed with FCD, we have not been able to show that the recurrence rate of CDI is different depending on the dosage regimen of fidaxomicin. Clinical trials or large observational studies comparing the two dosing regimens of fid …

And just submitted a book chapter on diagnosis and treatment of #Cdiff for @CMIMorg 2024 Update in Internal Medicine book wrote along w a fantastic colleague, Dr. @Chatterjee_MD - initially written in English, I translated into Spanish! @CCF_IMCHIEFS @Mud_Fud @ACPIMPhysicians pic.twitter.com/ZCUcI0uJjJ— Med Peds Hospitalist (@medpedshosp) February 28, 2023

TMC/UHCOP ID Fellow @TarynEubank drops updates on reduced #vanco susceptibility in #Cdiff for ASM-TMC MicroTalks 4 pm March 1 https://t.co/fXF1rosKhy— UH Pharmacy (@UH_Pharmacy) February 27, 2023

Some of the current scales may not be appropriate to discriminate severity in patients with cancer. The variables in this study associated with unfavorable outcomes could be evaluated in prospective studies to develop prognostic scores that identify susceptible patients, especially in immunocompromi …

Impact of Clostridium difficile infection on stroke patients in rehabilitation wards

Intravenous metronidazole for fulminant Clostridioides difficile infection

A large proportions of patients with C difficile infections do not respond to metronidazole.

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.

Researchers assessed the effects of adjunctive eravacycline therapy in patients with recurrent, severe, or fulminant Clostridioides difficile infection.

Impact of Clostridium difficile infection on stroke patients in rehabilitation wards

Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and mortality, especially for high-risk groups that include immunocompromised patients. Both the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America (IDSA/SHEA) …

Extended infusion piperacillin/tazobactam was associated with lower odds of 14-day mortality compared to standard infusion piperacillin/tazobactam.

Patients with inflammatory bowel disease (IBD) have a higher incidence of Clostridioides difficile infection (CDI). Previous studies have demonstrated negative clinical outcomes in IBD patients with CDI compared to patients without CDI. The clinical presentation of CDI is indistinguishable from IBD …

Sky-high costs with little wiggle room to negotiate mean fidaxomicin remains underprescribed for recurrent C diff, despite favorable outcomes.

Co-administration of probiotics and antibiotics has been used to prevent or treat primary Clostridioides difficile (pCDI), and the closer the interval between the combination, the more effective it is, but the reason behind this is unknown. In this study, the cell-free culture supernatant (CFCS) of …

Clostridioides difficile is a common cause of community-associated and health care-associated infections. Older adults are disproportionately affected, and long-term care facilities (LTCFs) have borne a substantial proportion of the burden of C difficile infection (CDI). Recurrences of CDI are commo …

The stubborn superbug Clostridium difficile, or C. diff, may have met its match. A esearcher is reporting the first well-controlled study to demonstrate the effectiveness of a new medicine for patients with the debilitating recurrent infection and disease.

Although fecal microbiota, live-jslm (Rebyota; RBX2660) is the first fecal microbiota product approved by the FDA, there are other microbiota-based agents in the pipeline.

Advances in Therapy - The gut microbiota is intrinsically linked to human health; disturbances in microbial homeostasis are implicated in both intestinal and extraintestinal disorders. Probiotics...

Join us for a live, virtual CME/CE-certified 90-minute symposia to gain expert insights on various aspects of CDI care including critical evaluations of clinical practice guidelines and approaches to individualize care by incorporating the patient voice in management decisions. Register Today

Clinical Decisions from The New England Journal of Medicine — Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.